Sulbactam, a new beta-lactamase inhibitor, has pharmacokinetic characteristics in humans similar to those of ampicillin and amoxicillin. Its half-life in humans is approximately 1 h. In a two-compartment pharmacokinetic model, the apparent volume of distribution for the central compartment is approximately 12 liters, and half of the dose is found in the central compartment in the postdistributive phase. Approximately 75% of a parenteral dose is excreted unchanged in urine. The coadministration of sulbactam with ampicillin, penicillin G, or cefoperazone has essentially no effect upon the kinetics of either the beta-lactam antibiotic or sulbactam.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC184789PMC
http://dx.doi.org/10.1128/AAC.23.5.692DOI Listing

Publication Analysis

Top Keywords

central compartment
8
pharmacokinetics sulbactam
4
sulbactam humans
4
humans sulbactam
4
sulbactam beta-lactamase
4
beta-lactamase inhibitor
4
inhibitor pharmacokinetic
4
pharmacokinetic characteristics
4
characteristics humans
4
humans ampicillin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!